📰 Newspapers

Judge approves $7.25bn settlement for Roundup weedkiller cancer claims

Judge approves $7.25bn settlement for Roundup weedkiller cancer claims

The settlement will be paid by Bayer to users who already have non-Hodgkin lymphoma and those who fall ill in the future.

A Missouri judge on Friday approved a $7.25bn (£5.5bn) settlement stemming from lawsuits ⁠alleging that Bayer's weedkiller Roundup causes cancer.

Judge Timothy Boyer said the settlement was "fair, reasonable, and adequate".

Bayer, the German bio-tech giant, had proposed paying the $7.25bn to definitively resolve a legal battle in the US.

The nationwide settlement will be paid to Roundup users who are already sick with non-Hodgkin lymphoma and those who fall ill in the future.

The company had already paid roughly $10bn to resolve litigation related to Roundup.

The settlements to participants range from $10,000 to $165,000, depending on how frequently they used the product, when they were diagnosed with the cancer and how severe their illness was.

Bayer will make annual payments into a fund for up to 21 years, providing as much as $7.25bn.

Some attorneys had objected to the settlement funds, arguing they were not enough, but the judge said he did not want to delay payouts to sick victims.

Bayer denies that its Roundup product causes cancer.

The settlement comes after the Supreme Court in June ruled in favour of Bayer, overturning a $1.25m settlement for a Missouri man who said Roundup and its ingredient glyphosate was to blame for his non-Hodgkin lymphoma.

In brief

A Missouri judge on Friday approved a $7.25bn (£5.5bn) settlement stemming from lawsuits ⁠alleging that Bayer's weedkiller Roundup causes cancer. Judge Timothy Boyer said the settlement was "fair, reasonable, and adequate". The company had already paid roughly $10bn to resolve litigation related to Roundup. Bayer denies that its Roundup product causes cancer.

This is the opening of the story, shared with credit to BBC News — US & Canada. The rest of the report — with every detail — continues on the publisher’s website.

Continue reading at BBC News — US & Canada ↗

Cookie settings

Choose which cookies we may use. You can change this at any time from Cookie settings in the footer. Details of each cookie are in the Cookie Policy.

Strictly necessary

Needed for sign-in, security, payments and remembering these choices. Always on.

Preferences

Remember settings such as dark mode.

Analytics & performance

Help us count visits, understand which pages, devices and countries our readers use, and measure how well the site performs – anonymous and aggregated.

Advertising & marketing

Lets advertising partners show and personalise adverts, measure impressions, clicks and visits, prevent ad fraud and pay us – this is how the free site is funded.

🔔 News notifications

Get headlines from NewsHub on this device — even when the site is closed.

You can switch this off at any time. Works on Android, Windows, Mac and Linux browsers; on iPhone/iPad add the site to your Home Screen first.